findmyKOL
Clinical trialNCT02593487UnknownPhase 4Interventional

Effect of Rosuvastatin Therapy on HDL2 Level

SponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityEnrollment300Coronary Heart DiseaseHyperlipemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Xu-kai Wang, PhD

    the Department of Cardiology, Daping Hospital, the Third Military Medical University

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Xu-Kai Wang

    Chongqing, Chongqing Municipality, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2015
Primary completion
31 Dec 2016
Completion
30 Jun 2017
Last update posted
3 Nov 2015
Registered enrollment
300
Registry id
NCT02593487

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.